To assess acute gastrointestinal (GI) and genitourinary (GU) toxicities in patients with localized prostate cancer treated with a sequential dose escalation hypofractionated intensitymodulated radiotherapy (IMRT) study using two different delivery methods. Since 2003, 88 and 48 patients were sequentially treated to 56 Gy and to 60 Gy (4 Gy/fraction twice weekly), respectively. IMRT with 6 MV beams was delivered with five fields in Geneva and with nine in Barcelona. Acute GI and GU side effects were scored weekly during treatment and 6 weeks after treatment completion using the Radiation Therapy Oncology Group (RTOG) toxicity scale. Clinical, technical, and dosimetric parameters were analyzed in order to assess for a potential correlation with toxicity.
Introduction
Several randomized phase III clinical trials assessing dose escalation with radiotherapy (RT) above 70 Gy have shown improved outcomes but with a higher incidence of urinary and rectal toxicity rates for those patients treated in the high dose arms (1) (2) (3) (4) . In order to pursue the search for an improved outcome with dose escalation but with reduced side effects several authors have tested doses above 80 Gy (or equivalent) as part of well established pilot studies or Phase-II trials using intensity modulated X-ray beams (IMRT), thus allowing for a better dose distribution (5) (6) .
Dose escalation for prostate cancer may also be feasible delivering higher than standard dose per fraction (hypofractionation) with or without IMRT. Indeed, several experimental and clinical studies have suggested a relatively low α/β ratio for prostate cancer cure ranging between 0.8-2.2 Gy, values much less than the corresponding α/β ratio for late responding tissues (i.e., 3-5 Gy) (7-9). These low α/β values may relate to the relatively long doubling time of prostate cancer cells Technology in Cancer Research & Treatment, Volume 9, Number 3, June 2010 and to their effective repair capacity of sublethal radiation damages at low dose per fraction (9). Thus, these findings are the rationale for using larger than standard dose fractions (hypofractionated RT) to treat with curative intent localized prostate cancers. The reduction in the total number of fractions may most likely improve patient's compliance and potentially reduce the cost of treatment. Several trials have been published so far with encouraging preliminary results (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
In the present report, we aim to present the results on acute toxicity in patients treated for localized prostate cancer with a sequential dose escalation hypofractionated IMRT schedule (14 × 4 Gy and 15 × 4 Gy) using two different IMRT delivery systems.
Methods and Materials
Between 2003 and 2007 a total of 136 patients from Geneva (GVA) and Barcelona (BCN) with histologically confirmed prostate cancer with stage T1-3N0M0 with any Gleason score and prostate-specific antigen (PSA) consented to be treated according to a hypofractionated IMRT schedule. A written informed consent form was required in BCN where the study began in September 2003 but not in GVA where hypofractionation was used since December 2005 as part of a pilot study aiming to develop IMRT and, in addition, to establish the basis for a randomized Phase-II multicenter trial on hypofractionated RT. Clinical staging with digital rectal examination and pretreatment PSA were performed in all patients. An abdominal computed tomography (CT) scan and a bone scan were performed only in patients with PSA  10 ng/mL and/ or Gleason score  7. Contrast enhanced endorectal magnetic resonance imaging was performed in 111 patients after diagnosis (a minimum of 4-6 weeks after biopsy). The patient and tumor characteristics are shown in Table I . Median age at diagnosis was 68.9 years (range, 51.2-85.9). The median value of PSA at diagnosis was 7.5 ng/mL (range, 0.62-80). Androgen deprivation therapy (ADT) was prescribed to 37 patients (27%) associating an antiandrogen (bicalutamide, 50 mg qd) during 30 days and a LHRH agonists (goserelin or leuprolide) before and during RT.
A simulation CT was performed with patients lying in the supine position. Three-mm thick CT images were acquired for planning purposes from L5 through the ischial tuberosities. Patients were instructed to empty their bladder before simulation and successively before every IMRT fraction. The patients in the study initially used a rectal enema before simulation and before each treatment fraction in order to reduce inter-and intra-fraction target motion. The first 22 patients in this group (treated to 56 Gy in BCN) were simulated and treated using a rectal balloon inflated with 60cc of air after purging the rectum as part of an optimization study for internal organ motion reduction. Later on, rectal purging before treatment was done only in patients with medium-to-large rectal volumes at simulation (i.e., .60 cc) as we observed that internal organ motion over the treatment was maximal in these patients and minimal in patients with relatively small rectums (i.e., 60 cc) at simulation.
The clinical target volume (CTV) included the prostate and the seminal vesicles (SV) without margins. The SV were included in the CTV when the risk of SV involvement was  15% for lesions . cT2 as determined by the formula published by Diaz et al., (22) or when SV or their confluence with the vas deferens were shown to be infiltrated on endorectal MRI. The safety margin around the CTV in order to define the planning target volume (PTV) was of 10 mm in all directions except posteriorly (towards the rectal wall) Abbreviations: ADT = androgen deprivation therapy; MRI 5 magnetic resonance imaging; PNI 5 perineural invasion; PSA 5 prostate-specific antigen; *National Comprehensive Cancer Network (NCCN) risk grouping system.
where a reduced margin of 6 mm was employed. Organs at risk (OAR) were the bladder, the rectum, the penis bulb, and the femoral heads. The rectum was outlined for all patients from 9 mm above to 9 mm below the CTV. In the 22 patients treated with 56 Gy in BCN with a rectal balloon, the urethra was defined as an additional OAR using the simulation CT images of the prostate and the corresponding fusion images of the diagnostic endorectal MRI, both studies done in similar conditions (the rectal balloon used during radiotherapy was the same as the endorectal probe used for MRI studies). AcQSim (AcQSim ® System, Philips Medical System, Cleveland OH) and a BrainSCAN (BrainLAB ® AG, Heimstetten, Germany) were the two treatment planning systems used for contouring in GVA and BCN, respectively.
A sequential dose escalation hypofractionated IMRT protocol was adopted aiming to deliver 56 and 60 in 4 Gy fractions, 2 times a week (i.e., 14 × 4 Gy and 15 × 4 Gy) to 88 and 48 patients, respectively. The migration from 56 to 60 Gy was undertaken in 2006 when a preliminary evaluation showed lower than average early and late toxicities for patients treated to 56 Gy in BCN compared to standard fractionated RT to 74 Gy or more. The estimated equivalent normalized total dose in 2 Gy/fraction (NTD 2 ) for the two fractionation schemes, assuming an α/β ratio 5 2 Gy for prostate cancer cells, was 84 and 90 Gy, respectively. Table II presents the patient treatment characteristics.
In GVA 43 patients were treated (19 with 56 Gy and 24 with 60 Gy) with a five non-opposed 6-MV X-ray beam technique (one posterior, two oblique posterior and two oblique anterior fields) from a linear accelerator with static multileaf collimation (Varian 2100 CD, Palo Alto, CA). Inverse planning before treatment was performed with Eclipse ® (Varian associates) for a dosimetric optimization. In BCN 93 patients were treated (69 with 56 Gy and 24 with 60 Gy) with a commercially available extracranial stereotactic system (ExacTrac, BrainLAB ® AG, Heimstetten, Germany) and nine 6 MV X-ray beams IMRT with a micromultileaf collimator based linear accelerator (Novalis, BrainLAB ® AG, Heimstetten, Germany). Inverse planning and dosimetric optimization were performed with BrainSCAN. Daily setup position was verified using portal images matched with digitally reconstructed radiographs before every IMRT session.
In BCN the stereotactic setup with ExacTrac was based on an infrared guided repositioning device with the patient immobilized in a customized vacuum body cast (23).
The dose was prescribed at the International Commission on Radiation Units and Measurements (ICRU) reference point. PTV was planned to receive a minimum dose (D min ) and a maximum dose (D max ) of 95% and 117% of the prescribed dose, respectively. Priority was given to normal tissue dose-volume constraints over the 95% dose coverage of the PTV. D max for the rectum and bladder was  95% of the prescribed dose,  30% of the rectum or bladder was to receive 90% of the prescribed dose, and  50% of the rectum or bladder was to receive 50% of the prescribed dose. The femoral heads were planned to receive a D max of 30 Gy to  5% and a dose of 20 Gy to  50% of their volumes. In order to limit the maximal dose to the bladder and the rectum, overlap volumes (i.e., PTV-bladder and PTV-rectum) were created in GVA but not in BCN. PTVbladder and PTV-rectum overlaps were constrained to receive a D min of 92.8% and 85.7% of the prescribed dose, respectively. In the 22 patients treated with a rectal balloon, the first 40 Gy were delivered to the whole prostate, whereas the final 16 Gy were delivered trying to spare the urethra plus a 5 mm rim of surrounding prostatic tissue from the high dose volume.
Acute gastrointestinal (GI) and genitourinary (GU) toxicities were assessed using the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria (24) once-a-week while on treatment and 6 weeks to 3 months after treatment completion. Grade 1-2 toxicities were analyzed together in order to avoid the interobserver variability in the drug prescription. Acute toxicity was correlated with treatment related variables using the chi-square test and Student's t-test for the statistical analysis. The following factors were analyzed for their possible relationship with acute toxicity: dose groups (56 vs. 60 Gy); treatment technique (GVA vs. BCN); impact of rectal enema before each IMRT fraction; impact of rectal balloon for internal organ immobilisation; area under the curve of rectal and bladder dose-volume histograms (AUC-DVHs) with the two different IMRT techniques; and the use of ADT.
Results
All 136 patients completed treatment without interruption. Grade 1-2 GU toxicity was seen during and after treatment in 64% and 24% of cases, respectively. Thirty-two percent an attempt to spare the urethra was also undertaken in those patients treated with the rectal balloon that translated in a trend for a lower risk of Grade 1-2 GU toxicity (59%) compared to patients treated without urethral sparing in the same group of patients (79%) (p 5 0.08).
No significant differences were observed between rectal and bladder AUC-DVH (.0 Gy) and Grade 0 vs. Grade 1-2 GI and GU toxicities, respectively both for patients treated in GVA and in BCN. However, rectal AUC-DVHs . 50 Gy for patients with Grade 1-2 toxicity was higher in BCN than GVA (p 5 0.002), possibly explaining the higher GI toxicity presented by these patients.
Patients receiving concomitant ADT presented a higher rate of Grade 1-2 GU toxicity 6 weeks after the end of the treatment (38% vs. 19%, p 5 0.02) as compared to patients treated with exclusive IMRT, while no correlation was found during the treatment and with GI toxicity.
Discussion
In agreement with recent publications suggesting α/β values as low as 1 to 3 Gy for prostate cancer several dose escalation studies with hypofractionation have been conducted so far expecting to improve the therapeutic ratio (10-21). These studies, most frequently using sophisticated dose delivery techniques with accurate daily target localization, have shown acceptable acute rectal and urinary toxicity levels. Nevertheless an optimal hypofractionation schedule has not been established yet. The "ideal" fraction size should optimally match the fractionation sensitivity of the tumor and the surrounding normal tissues, (the rectum and the bladder), respectively.
of patients presented with Grade 2 GU toxicity during treatment and were treated with selective α-1 blockers or nonsteroidal anti-inflammatory drugs (NSAIDs). Only one patient treated to 60 Gy at BCN developed an acute Grade 4 urinary retention during treatment that resolved spontaneously a few weeks after the end of the RT. Grade 1-2 GI toxicity was seen during and after treatment in 35% and 12%, respectively. Only 8% of patients presented with Grade 2 GI toxicity and were treated with either NSAIDs or topical treatment for the ano-rectal region. There was no incidence of Grade 3 or higher GI toxicity.
There was no significant correlation between dose (56 vs. 60 Gy) and both GI and urinary toxicities during and after treatment completion. When comparing the two different treatment delivery techniques (BCN vs. GVA) we observed that patients treated to 60 Gy in GVA experienced a higher rate of Grade 1-2 GU toxicity during the course of radiotherapy than patients treated in BCN (75% vs. 33%, respectively; p 5 0.01). Patients treated in BCN (excluding those treated with a rectal balloon), however, presented with a higher rate of GI Grade 1-2 toxicity both while on treatment and 6 weeks after treatment completion (p 5 0.02). GI and GU acute morbidities stratified by dose and treatment delivery techniques are presented in Figures 1 and 2 .
Preparing patients with a rectal enema before every treatment in order to potentially reduce prostate motion was not correlated with a lower risk of toxicity, especially at the GI toxicity, except for the 22 patients from BCN treated to 56 Gy with a rectal balloon who presented a lower rate of Grade 1-2 rectal toxicity (14%) compared to patients treated to 56 Gy without balloon (42%) (p 5 0.02). Furthermore, The variability in patient selection and differences in dosimetric optimization criteria and reliability of treatment implementation in optimal or less optimal repositioning conditions may limit a fair comparison of toxicity profiles from different IMRT hypofractionated treatment protocols. Indeed, Martin et al., (19) reported slightly lower acute toxicity rates than ours even though the BED 10 of their hypofractionated IMRT series was higher than ours (i.e., 62.9 Gy vs. 47.5-49.9Gy). This discrepancy can be explained by a successful dose distribution optimization with a lower dose to the OAR, especially the rectal wall, as their treatments were limited to the prostate gland (excluding the SV) in addition to the optimization of treatment reproducibility with the use of fiducial markers to track the prostate position on portal vision before every treatment session. Although, in the hypofractionated IMRT series by Kupelian et al., (15) , the BED 10 was the same as the above presented value for Martin et al., (i.e., 62.9 Gy), the former reported on a higher rate of acute Grade 1-2 rectal toxicity than the later and also than ours (49% vs. 33% vs. 35%). It is possible that the dosimetric and treatment conditions of the Kupelian et al., series where similar to ours thus possibly reflecting a pure dose effect (i.e., a higher BED 10 correlates with a higher rate of acute rectal toxicity).
In order to present an intra-institutional benchmark of acute toxicity with standard fractionation and three-dimensional conformal RT (3D-CRT) without dosimetric optimization, we have added in Table III the results on acute toxicity for an historical series of 408 patients treated in GVA with 6-fields 3D-CRT to 74-78.4 Gy in 1.8-2 Gy daily fractions. Indeed, BED 10 values were higher in this series than in our hypofractionated IMRT (52-57.9 Gy vs. 47.5-49.9 Gy) and the rate of GI Grade 1-2 acute toxicity was accordingly higher (52% Using 4 Gy fractions, twice-a week, for a total dose of 56 or 60 Gy may be most convenient to patients and a potential relief for busy radiation oncology departments. Indeed, assuming that the NTD 2 for the present hypofractionated treatment schedules were 84 and 90 Gy, respectively, the same doses delivered in standard 2Gy/fraction 5 days-a-week represent 42 to 45 treatment days compared to only 14 to 15 with our hypofractionated schedules.
In order to optimally reduce the intensity of acute mucosal reactions the overall treatment time was limited to seven (56 Gy) and seven and a half weeks (60 Gy) for a weekly dose of ,10 Gy. Furthermore, based on the assumption of long cell turnover times for prostate cancer cells we did not aim to accelerate the treatment and shorten the overall treatment time. Keeping the dose below 10 Gy/week (similar to standard fractionation schedules), may explain the relatively low toxicity profile observed in our patients. Comparing the biological effective dose for acute mucosal reactions, considering an α/β ratio 5 10 Gy (BED 10 ), and correcting for cell repopulation during a several week course of RT (18, 25) , the toxicity rates of the two hypofractionated RT schedules presented in this paper were among the lowest compared to similar hypofractionation studies as shown in Table III . Although different treatment related-factors can limit the ability to derive strong conclusions from a comparative analysis between studies it may be reasonable to conclude that the relatively low BED 10 values with our fractionation schedule may explain, at least in part, our relatively low acute toxicities rates. The low BED 10 values in our study are below the 59-63 Gy 10 threshold value for mucosal tolerance as reported by Fowler et al., (17, 25) , above which the risk to develop acute toxicity increases significantly. for all patients there. Unfortunately, in BCN no dose constraints were established for the overlaps PTV-rectum and PTV-bladder due to the unavailability of tools allowing the performance of boolean operations with volumes. This may explain the significantly higher, though acceptable, toxicity rates in BCN based exclusively on dosimetric parameters (i.e., higher AUC-DVH for the rectum in BCN than in GVA for patients developing acute effects).
A reduced rectal toxicity and a trend for a lower urinary toxicity in the 22 patients treated with a rectal balloon potentially sparing rectal mucosa and limiting the dose to the urethra suggest that any optimization effort in improving treatment set-up reproducibility may have a marked influence in the reduction of treatment-related toxicity rates. Further optimization of patient and organ immobilization with contemporary image-guided treatment monitoring techniques for prostate cancer is possible today with the use of intraprostatic fiducial gold markers or cone beam CT systems.
In our study, ADT was a significant predictor of acute Grade 1-2 GU morbidity after the end of the radiotherapy. Despite a theoretical advantage in the incidence of urinary toxicity with the use of ADT due to a 50% reduction in the bladder DVH as a consequence of the prostate cytoreduction (26), our results are, however, in agreement with other published series that showed an increased likelihood of acute GU toxicities with hormonal treatment (27-28).
vs. 35%). Furthermore, the estimated BED 10 values for acute mucosal response from Madsen et al., (18) , with their 5 × 6.7 Gy hypofractionated treatment schedule, was similar to the above quoted BED 10 values from the GVA standard fractionation series. Again, a lower toxicity rate was reported by Madsen et al., (39% vs. 52%) , likely translating the benefit of a dosimetrically based treatment optimization and the stereotactic treatment conditions of their hypofractionated treatment protocol.
Thus, summarizing the discussion above, data presented in this paper and in the reports quoted in Table III suggest that optimal toxicity profiles using hypofractionated schedules are mostly related to BED for acute mucosal reactions, to treatment delivery techniques, and to patient and organ immobilization methods. IMRT optimization enables to deliver higher doses to the CTV than standard 3D-CRT sparing at the same time the surrounding OAR. Indeed, one of the strong points of the present report, compared to others, is that, independently of the unique dose-fractionation schedules used to treat patient both in BCN and GVA, we aimed to assess two different planning and treatment delivery methods for the same dose prescription. The linac from BrainLAB used in BCN was limited by a reduced field size (10 × 10 cm maximal collimator opening) with penumbra and hot spot problems for large PTVs. Unlike the 5-field IMRT technique with the linac from Varian used in GVA, a 9-field IMRT technique in BCN most frequently helped to overcome this problem and was recommended In conclusion, the present dose escalation study to a dose of 56 or 60 Gy is feasible and is associated with a tolerable acute toxicity level. A longer follow-up of patients in this series will be necessary before establishing strong and reliable conclusions on late toxicity and outcome.
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